These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17534444)

  • 1. Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice.
    Seierstad T; Folkvord S; Røe K; Flatmark K; Skretting A; Olsen DR
    Neoplasia; 2007 May; 9(5):392-400. PubMed ID: 17534444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial neural networks for prediction of response to chemoradiation in HT29 xenografts.
    Kakar M; Seierstad T; Røe K; Olsen DR
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):506-11. PubMed ID: 19735875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models.
    Kolinsky K; Shen BQ; Zhang YE; Kohles J; Dugan U; Zioncheck TF; Heimbrook D; Packman K; Higgins B
    Mol Cancer Ther; 2009 Jan; 8(1):75-82. PubMed ID: 19139115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early changes in apparent diffusion coefficients predict radiosensitivity of human nasopharyngeal carcinoma xenografts.
    Pan J; Zang L; Zhang Y; Hong J; Yao Y; Zou C; Zhang L; Chen Y
    Laryngoscope; 2012 Apr; 122(4):839-43. PubMed ID: 22374860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
    Folkvord S; Flatmark K; Seierstad T; Røe K; Rasmussen H; Ree AH
    Radiother Oncol; 2008 Mar; 86(3):428-34. PubMed ID: 18006097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
    Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
    Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model.
    Seierstad T; Røe K; Olsen DR
    Radiother Oncol; 2007 Nov; 85(2):187-94. PubMed ID: 17937968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck.
    Rabinowits G; Bhupalam L; Miller DM; Kloecker GH; Laber DA
    Am J Med Sci; 2010 Feb; 339(2):148-51. PubMed ID: 20087165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction.
    Hwang SJ; Park JW; Lee SD; Kim GJ; Sin CH; Nam SH; Kim BS
    Korean J Intern Med; 2006 Dec; 21(4):252-5. PubMed ID: 17249509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer.
    Quek R; Lim WT; Foo KF; Koo WH; A-Manaf A; Toh HC
    Acta Oncol; 2007; 46(7):1032-4. PubMed ID: 17917832
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
    Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
    Blanquicett C; Saif MW; Buchsbaum DJ; Eloubeidi M; Vickers SM; Chhieng DC; Carpenter MD; Sellers JC; Russo S; Diasio RB; Johnson MR
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8773-81. PubMed ID: 16361565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is apparent diffusion coefficient reliable and accurate for monitoring effects of antiangiogenic treatment in a longitudinal study?
    Suh JY; Cho G; Song Y; Lee CK; Kang JS; Kang MR; Park SB; Kim YR; Kim JK
    J Magn Reson Imaging; 2012 Jun; 35(6):1430-6. PubMed ID: 22314928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravoxel incoherent motion diffusion-weighted imaging for monitoring chemotherapeutic efficacy in gastric cancer.
    Song XL; Kang HK; Jeong GW; Ahn KY; Jeong YY; Kang YJ; Cho HJ; Moon CM
    World J Gastroenterol; 2016 Jun; 22(24):5520-31. PubMed ID: 27350730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
    Ilhan-Mutlu A; Preusser M; Schoppmann SF; Asari R; Ba-Ssalamah A; Schwameis K; Pluschnig U; Birner P; Püspök A; Zacherl J; Hejna M
    Anticancer Res; 2013 Aug; 33(8):3455-9. PubMed ID: 23898119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
    Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K
    Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
    Chu E; Schulman KL; McKenna EF; Cartwright T
    Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
    Zhou J; Tang ZY; Fan J; Wu ZQ; Ji Y; Xiao YS; Shi YH; Li XM; Sun QM; Liu YK; Ye SL
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6030-7. PubMed ID: 14676129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.